CD38 inhibition using the anti-CD38 antibody daratumumab (Darzalex®, Genmab, Copenhagen, Denmark) together with nivolumab (anti PD-1 IgG4) is being analysed in a phase I/II study of 120 patients with advanced pancreatic, lung and breast cancer (NCT3098550). Here, CD38 is linked to breast cancer.